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Visceral leishmaniasis is a vector-borne tropical disease associated with a spectrum of clinical manifestations and 
immunosuppression leading to parasite survival. Chemokines which act as chemo-attractants for generating innate immune 
responses are significant in bringing innate and adaptive responses side by side for combating against infection. The 
independency and interdependency of regulatory T cells and Th17 cells on Th1/Th2 signalling pathways and an imbalance 
in immune responses could lead to disease progression. Although Interleukin- (IL-)12 is crucial in generating protective 
Th1 response against the disease, various members of  the IL-12 family perform diverse immune functions due to their 
chain pairing promiscuity. This review focuses on the immunopathogenesis of VL by chronologically summarising the 
developments in the studies of the immune regulation as well as the mechanisms involved. A better understanding of the 
innate and adaptive immune functioning of the host could aid in rational control and better therapeutic intervention of the 
disease.
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Introduction
Visceral leishmaniasis (VL), also known as kala-azar, 
is caused by the protozoan parasites of the genus 
Leishmania that includes Leishmania donovani, 
Leishmania chagasi and Leishmania infantum. VL 
is prevalent in more than eighty countries (Choi and 
Lerner, 2001) worldwide. Of  them approximately 
90% of VL cases are reported in Bangladesh, India, 
Ethiopia, Sudan, South Sudan, and Brazil (Alvar et 
al., 2012). The characteristic symptoms of VL include 
irregular bouts of fever, substantial weight loss, 
swelling of the spleen and liver, and anaemia. The 
disease is fatal if left untreated. VL is an 
immunosuppressive disease with most of the patients 
showing negative leishmanin skin test (Gidwani et 
al., 2009). It could be an interesting topic to explore 
since the proliferative response of peripheral blood 
mononuclear cells (PBMC) from such active VL 
patients is poor.
In VL, the beginning of infection is marked by 
recruitment of innate immune cells such as, 
neutrophils, macrophages, natural killer (NK) cells 
and dendritic cells (DCs) at the site of infection due 
to the secretion of different chemoattractant proteins. 
Later these recruitments generate a mixed regulatory 
and inflammatory responses by secreting chemokines 
and cytokines. These responses are exhibited 
generally by low levels of IL-12 or IFN-  and elevated 
production of IL-10, TGF- , IL-4 and IL-13 in 
leishmanial antigens stimulated culture supernatants 
of VL patients. Contradictory reports are also there 
manifesting increased level of IFN-  m-RNA in both 
liver and spleen of the infected subjects (Saha et al. 
2007; Nylen et al. 2007; Sacks et al., 1987). Similar 
observations were made in murine VL, where both 
IL-10 and TNF-  production were found to be 
elevated in the spleen. TNF- , which is critical for 
the development of protective immunity, causes
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granuloma formation in the liver, but may also induce
IL-10 secretion to control the tissue damage (Ato et
al., 2002). Enhanced IL-10, besides inhibiting
macrophage activation and granuloma formation, also
promotes parasite persistence through its
immunosuppressive mechanisms (Ato et al., 2002;
Murray et al., 2000; Stanley et al., 2007; Buxbaum
2013; Murray et al., 2002).
IL-27, a cytokine central in regulation of Th17
cells, is mainly produced by antigen presenting cells.
Studies in mice have demonstrated that this cytokine
can inhibit the differentiation of Th17 cells. IL-27
could also act synergistically with IL-10 and TGF-
in inducing disease pathogenicity  (Chen and Liu
2009; Belkaid et al., 2001). TGF- , on the other hand,
is essential for the induction of FoxP3+ Regulatory T
(Treg) cells. Additionally it could also inhibit the
generation of Th1 cells, leading to disease progression
(Batten et al., 2006). Treg cells are considered as
masters of immune regulation that promote bystander
suppression of effector T cells and infectious
tolerance (Banchereau et al., 2012). Although Tregs
have mostly been shown to promote Th2 response in
cutaneous leishmaniasis (CL) in human and mice
(Tang and Bluestone 2008; Lund et al., 2008;
Rodriguez-Pinto et al., 2012), some reports also
suggest their involvement in controlling disease
manifestation by facilitating timely homing of
immune effector cells to the site of infection
(Rodriguez-Pinto et al., 2012). In VL such reports
are lacking and more studies on human and mice are
required to establish the role of Tregs. Moreover, it
would be interesting to investigate the possible
involvement of IL-35 producing T cells in VL as it
was recently reported to play a Th2 promoting
response in autoimmune diseases (Collison et al.,
2010). In the present review the initial part deals with
the current understanding of the immunology of
Leishmania infection and the dynamicity of the host
pathogen interaction. We considered different
evidences available to explain the immunoregulatory
role of diverse immune cells and their cytokines with
the course of infection in murine VL. It is an attempt
to summarise the new concepts developed so far in
terms of roles played by the different subsets of T
cells, Th17 cells and their cytokines during disease.
These are followed by a concise description on
modulation of signalling pathways by L. donovani.
At the end, a brief description on the shortcomings
in the study of immunology of VL and challenge to
overcome the disease has been incorporated as future
prospects.
Innate Immune Response
Infection with Leishmania begins when an infected
female sand fly suck blood from its host. It has been
found that few thousands of meta-cyclic
promastigotes present in sand fly saliva are sufficient
to establish disease progression causing wounding
of the microvasculature that creates a hemorrhagic
pool. Sand fly saliva contains well characterized
molecules that have several activities, including
vasodilation, inhibition of coagulation and
immunomodulatory effects (Okwor et al., 2009;
Sacks D and Kamhawi S 2001). It also contains few
uncharacterized molecules that could attract
neutrophils and macrophages (Zer et al., 2001) and
recruit them to local inflammatory reaction (Kamhawi
et al., 2000).
Neutrophils
Neutrophils are the first cells to arrive at the site of
Leishmania infection (Muller et al., 2001), where they
release neutrophil extracellular traps (NETs). NETs
are composed of filamentous DNA with antimicrobial
peptides and found to be induce by Leishmania
surface proteins like GP63 and lipophosphoglycan
(LPG) (Bhowmick et al., 2008; Brinkmann et al.,
2004). In vitro experiments using human neutrophils
and Leishmania amazonensis promastigotes have
revealed that Leishmania are trapped and killed by
NETs. Moreover Leishmania braziliensis elimination
is dependent on the interaction between neutrophils
and macrophages and was shown to be associated
with tumor necrosis factor-  (TNF- ) as well as
superoxide production. Co-operation between
neutrophils and macrophages towards parasite
elimination was also observed in experiments
performed with L. braziliensis infected human cells
(Bhowmick et al., 2008; Brinkmann et al., 2004;
Guimaraes-Costa et al., 2009).
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However, neutrophils have proved to be
beneficial for survival of Leishmania in infected
tissues. Indeed, Leishmania have been found to
extend lifespan of these cells where they can survive
for hours to days after infection. The infected
neutrophils secrete chemokines like CXCL8 (also
known as IL-8) (Laufs et al., 2002) and macrophage
inflammatory protein (MIP)-1  which play a critical
role in attracting more neutrophils and macrophages,
respectively, to the site of infection. These neutrophils
when taken up by macrophages evade their
antimicrobial responses leading to a ‘silent’ entry of
these parasites into their host macrophages.  (van
Zandbergen et al., 2004). Laskay and colleagues,
(2003) coined a new term ‘Trojan Horses’ for
neutrophils which help promastigotes to achieve this
goal (Fig. 1). They observed that L. major
promastigotes were readily phagocytosed by
neutrophils in vitro, but survived within their
phagosomes. The infected neutrophils were induced
to undergo apoptosis and became a phagocytic meal
for macrophages. As apoptotic neutrophils are
phagocytosed through receptor-mediated pathways
that fail to trigger macrophage defence responses,
their cargoes of promastigotes are thereby efficiently
and safely shuttled into the macrophage phagosomes
(Laskay et al., 2003; Ravichandran and Lorenz
2007). However, it has been shown in an in situ
imaging study that most of the infected neutrophils
rapidly engulfing promastigotes, are short-lived and
release the parasites before being phagocytosed by
the macrophages. Moreover, the observation that the
parasite burden of macrophages and DCs isolated
from the mice remains unchanged even after
neutrophil depletion (Peters et al., 2008), suggest that
the neutrophils may merely scavenge the parasites
that are otherwise ignored. Although neutrophils
clearly participate in the early response to infection,
their role as a “Trojan Horse” has yet to be confirmed.
Macrophages
Macrophages are the second wave of cells that enter
the site of Leishmania infection. They serve as host
for parasite replication and a source of cytokines
modulating the T cell-mediated immune responses.
Moreover, after appropriate activation by Th1 cells,
they act as effector cells for intracellular parasite
killing.  Promastigotes are rapidly phagocytosed by
dermal macrophages (Locksley et al., 1988) through
a complement receptor (CR)-3 dependent mechanism
(Mosser and Edelson 1985) and eventually
metamorphose to amastigotes. In infected
macrophages, amastigotes settle in acidic
parasitophorous vacuoles that exhibit most of the
features of phagolysosomes including the presence
of lysosome markers such as lysosomal associated
membrane protein (LAMP)-1, LAMP-2, and rab7p
(small GTP-binding proteins involved in vesicular
transport) (Dermine et al. 2005, Antoine et al., 1999;
Courre et al., 2002). Leishmania parasites have
evolved several mechanisms to avoid hydrolysis in
the host innate environment. For example, L.
donovani promastigotes inhibit the fusion of the
phagosome with hydrolase-enriched endocytic
organelles. This mechanism depends on the
promastigote cell surface molecule lipophospho-
glycan which prevents the formation of phagolyso-
some by disruption of lipid microdomains on the
phagosome membrane (Dermine et al., 2005).
Monocytes are attracted in the early stages of
infection by products of sand fly saliva (Zer 2001)
and later by chemokines such as MIP-1  (van
Zandbergen et al. 2004). Leishmania also produce
chemotactic factors which induces the macrophages
to secrete monocyte chemoattractant protein (MCP)-
1 and CXCL1 (keratinocyte derived cytokines) that
act as chemo-attractants for monocytes and
neutrophils (Fig. 1). CCL2 is MCP-1 homolog in
human macrophages (Deshmane et al. 2009;
Racoosin and Beverley 1997; van Zandbergen et al.
2002). CCL2 can also attract other cells such as NK
cells and DCs that are positive for the chemokine
receptor CCR2. In human leishmaniasis, CCL2 and
MIP-1  appear to be responsible for macrophage
activation in skin lesions (Ritter and Moll 2000).
Macrophages stimulated by the synergistic action of
CCL2 and IFN-  kill parasites in localized CL (Muzio
et al., 2000), while the occurrence of IL-4 in diffused
cutaneous leishmaniasis (DCL) lesions suppress
CCL2 expression and promote progression of the
disease. Therefore macrophages activated by
chemokines play a pivotal role in bringing innate and
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adaptive immune responses together during
Leishmania infection.
Natural Killer (NK) Cells
NK cells come to the site of infection as early as 24
hours after parasite invasion and then migrate to the
infected skin and draining LNs (Laskay et al. 1995).
The migration of NK cells correlates with the
expression of the NK cell-activating chemokine
CXCL10.  Moreover,  treatment of susceptible
BALB/c mice with recombinant CXCL10 results in
significantly increased NK cell cytotoxic activity in
the draining LN (Vester et al., 1999).  Previously NK
cells were thought to be non-essential for the ultimate
control of cutaneous leishmaniasis (CL) and VL as
NK cell deficient mice could heal their lesions
through IL-12 dependent IFN-  production by CD4+T
cells (Satoskar et al., 1999). But recent research
emphasizes  NK  cells  as  an  important source of
IFN-  that can elicit antileishmanial activity in
macrophages thereby mounting a protective Th1
response against the parasite (Bogdan 2012; Martin-
Fontecha et al., 2004).  It has been shown that antigen
specific CD4+ T cells are required for initiation of
NK cell activation in vivo upon L. major infection
(Bihl et al., 2010) demonstrating a bidirectional
regulation between innate and adaptive immunity.
Dendritic Cells (DCs)
Interaction of parasite reactive IgG with Fc  receptors
on DCs are essential for recognition and engulfment
of Leishmania parasite. It appears that at later stages
of infection, the balance between Fc R mediated
induction of IL-12 from DCs and Fc R associated
IL-10 release from infected macrophages is ultimately
responsible for disease outcome (Filardy et al., 2010).
MHC class I- and II-restricted antigen presentation
towards both CD4+ and CD8+ T cells, respectively,
by DCs is essential for appropriate T cell priming
against parasite antigens. Infected DCs are crucial
for T cell priming in CL, whereas infected
macrophages mainly contribute to MHC class II-
restricted CD4+ T cell restimulation (Kautz-Neu et
al., 2012). Mast cell primed DCs stimulate CD4+ T
cells to release IFN-  and IL-17, demonstrating that
DCs promote Th1 and Th17 responses which are
protective against murine CL. Moreover, interaction
of DCs with NKT cells determines Th1/Th2
differentiation (Dudeck et al., 2011).  DC derived
IL-6 acts as a key cytokine regulating the expansion
of CD4+CD25–FoxP3–IL-10+ T cells in vivo against
L. donovani infection (Wiethe et al., 2008; Stager et
al., 2006). In vivo studies on mice have shown that
CD11chi DCs, as well as a mixed CD11cint/lo cell
population, are capable of inhibiting host resistance
and promoting disease-associated pathology in
murine VL (Owens et al., 2012). Furthermore IL-
10+IL-27+ DCs are able to promote IL-10 production
by Th1 cells (Awasthi  et al., 2008) thereby
emphasizing the importance of CD11c+ cells in
priming of Th1 and Th17 subsets, subsequently as a
potential target for immunotherapy.
During cure in VL, IFN-  secreting neutrophil,
eosinophil and NK cells increase, accompanied by
increase in IL-12 producing monocytes. There is a
clear correlation between cytokine profile of the
innate immune cells and VL pathology, indicating
their pivotal role not only in the control of early
parasite growth and systemic spreading of
Leishmania, but also as relevant source of
immunoregulatory cytokines. The co-ordination of
innate immune response with adaptive immunity acts
as a major relevance for both control of parasitism
and morbidity (Peruhype-Magalhaes et al., 2005).
Thus, the innate immune cells may, in addition to
other factors, contribute significantly in regulating
T-cell response and cytokine microenvironment
during disease progression and are critical additive
to adaptive immunity for controlling the disease
outburst.
Adaptive Immunity
Chemokines may have a direct role in the
development of the IFN-  mediated Th1 response. L.
donovani infected mice lacking CCR5 or its ligand
MIP-1 , demonstrate a low antigen-specific IFN-
response during the early phases of infection. MIP-2
and CXCL1, the functional murine homologs of
human IL- 8, are rapidly produced in the skin by the
L. major infected macrophages which serve to recruit
neutrophils and DC at the site of infection (Modi and
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Yoshimura 1999; Racoosin and Beverley 1997).  In
murine VL, infected mice undergo a rapid hepatic
accumulation of MIP-1 , CCL2 and CXCL10
(Cotterell et al., 1999). Increased expression of
CXCL10 enables accelerated liver granuloma
formation and inflammatory response against the
parasite. Monocytic cells attracted by MIP-1  and
CCL2, following IFN-  stimulation, could be the
source of Th1-mobilizing chemokines such as
CXCL10 (Farber, 1997). Unlike liver cells, spleen
cells from L. infantum infected mice produce both
Th1- and Th2-type cytokines with the Th2-type
response being dominant. This is compatible with the
sustained expression of CCL2 rather than CXCL10,
thereby show an influx of macrophages rather than T
cells in the spleen (Rousseau et al., 2001). This
perhaps is the reason for parasite persistence in the
spleen whereas liver usually controls the infection
(Kaye et al., 2004). Hence, chemokines are crucial
both as chemoattractant for innate immune cells, and
in promoting early cell mediated immune responses
during VL in both human and mice.
Th1 and Th2 Cells
Higher TNF- , IFN- , IL-12, IL-4, and IL-10 levels
were observed in patient serum with active lesions,
whereas cured subjects produced only IFN-  at
elevated levels. These observations suggest the
presence of a mixed Th1/Th2 response during active
CL and a sustained Th1 response characterized by
elevated IFN-  levels, and down-regulation of  IL-4
and IL-10 production while cure (Castellano et al.,
2009; Kedzierski et al., 2008). In human, VL is
associated with increased production of multiple and
primarily pro-inflammatory cytokines and
chemokines. Patients have been found to have
elevated plasma protein levels of IL-1, IL-4, IL-10,
IL-6, IL-8, IL-12, IL-15, IFN-  inducible protein-10
(IP-10), IFN- , and TNF-  (Alvar et al., 2012; Ansari
et al., 2006; Kurkjian et al., 2006; Nylen and Sacks
2007) . Elevated levels of IL-10 and TGF-  have been
shown from PBMC of active VL patient (Saha et al.,
2006; Hailu et al., 2004). With treatment, IL-10
slowly decreases while IFN-  increases in liver and
spleen and attain their normal levels (Costa et al.,
2012). Elevated levels of IFN-  mRNA have been
found in target organs, such as the spleen and bone
marrow, during the acute phase of infection,
accompanied by increased levels of IL-10 (Nylen et
al., 2007; Nylen and Sacks 2007; Banerjee et al.,
2008). Some intriguing studies suggest that the pro-
inflammatory cytokines are not depressed rather they
are unresponsive to the stimuli of pro-inflammatory
cytokines (Hailu et al., 2004). The underlying causes
of such immunologic unresponsiveness remain a
subject of further investigation. Additionally the
development of VL in human is not driven by Th2
skewing per se but some unexploited mechanisms
may also contribute to the pathogenesis of the disease.
IL-10, which has been suggested to be induced
by high levels of TNF- (Ato et al., 2002) may serve
to control the tissue damage caused by TNF- . But
at the same time IL-10, secreted from macrophages,
promotes parasite persistence by inhibiting
macrophage activation (Murray 2002). IL-10 is a
regulatory cytokine, presumed to be induced as a part
of homeostatic network to protect tissue from
collateral damage caused by excessive inflammation.
Primarily it has suppressive effects on immune
function, targeting multiple activation and antigen
presentation pathways of macrophage and DC. It
renders macrophage unresponsive to activation
signals and acts on DCs causing them to down
regulated CCR7 and thereby loosing migratory
capacity preventing them from proper access of T
cell areas and effective priming of T cell responses
(Ato et al., 2002). Moreover, treatment with
pentavalent antimonials could inhibit IL-10
production leading to rapid granuloma formation and
parasite killing with subsequent increase in IFN-
production from Th1 cells. This is followed by
enhanced expression of IL-12, NO and inducible
nitric oxide synthase (iNOS) in infected tissue further
enhancing effectiveness of the drugs (Buxbaum et
al., 2013; Murray et al., 2003; Hailu et al., 2004;
Banerjee et al., 2008).
IFN- , the most important cytokine for Th1
response, is likely to be produced in lymphoid organs
where Leishmania proliferates. IFN-  along with IL-
12 has potential therapeutic efficacy and may enhance
vaccine efficiency. Immunotherapy with IFN- /IL-12
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prior to the infection restricts the early phase of the
infection in CL (Ota et al. 2008). Vaccination against
a progressive L. donovani infection could increase
the production of IFN- , IL-12 and NO and
downregulate IL-4 secretion thereby resulting in
decrease of parasite burden in liver and spleen
(Bhowmick and Ali 2009; Mazumdar et al., 2004).
Similar results were also obtained by IFN-
immunotherapy manifesting an enhanced Th1
response accompanied with down regulation of
disease promoting IL-4 and IL-10 (Bhowmick et al.,
2007).
IFN-  may act as a double edged sword while it
can stimulate macrophages and limit amastigote
replication when coupled with lipopolysaccharides,
it also promote amastigote survival and growth when
coupled with TNF-  (Colmenares et al., 2002; Qi et
al., 2004).  Thus, IFN-  may play a bidirectional role
at the level of parasite-macrophage interactions.  It
has a protective effect against infection when
optimally associated with other factors such as IL-
12 and NO and in the absence of such synergy it
promotes amastigote growth.
Accumulating reports from mouse model of
nonhealing or disseminating forms of leishmaniasis
has reinforced pathogenic mechanisms that take into
account the presence of parasite-driven Th1 responses
suppressed either in magnitude or function by IL-10
(Anderson et al., 2009). In mice, activated
Leishmania specific CD4+ T cells are detected in
draining LN as early as 16 h after infection. These
cells rapidly expand and differentiate into cytokine
secreting cells (Malherbe et al., 2000). Majority of
Leishmania specific CD4+ T cells differentiate into
Th1 cells that secrete IFN-  and/or TNF-  which
efficiently contribute to the parasite elimination
through different mechanisms including the activation
of macrophage. In contrast, genetically susceptible
BALB/c mice show T cell response dominated by
Th2 cells that secrete IL-4, IL-10, IL-5, and / or IL-
13. IL-4 initiates induction of Th2 differentiation
during progressive leishmaniasis in resistant mice but
may display beneficial responses in L. major
susceptible BALB/c mice. IL-4 is crucial in priming
CD8+ T cells and protection against VL during
vaccination. IL-4 has major role in differentiation and
activation of CD4+ T cells, B cells and macrophage
during infection (Biedermann et al., 2001; Ghalib et
al., 1993; Stager et al., 2003). Infection with
Leishmania also results in the activation and
expansion of parasite specific CD8+ T cells. Upon
infection expansion of T cells and their rapid
recruitment to lymph nodes as well as the restriction
of IL-13 and IL-10 production leading to higher IFN-
/IL-10 ratio play an important role in protection
against Leishmania.
Central Versus Effector Memory Cells
Memory cells have been broadly classified into two
types-central and effector. Central memory cells home
to primary lymphoid organs and proliferate to perform
effector function only after secondary stimulation.
In contrast, effector memory cells do not proliferate
but secrete effector cytokines due to antigenic
stimulation (Lanzavecchia and Sallusto 2005).
Central memory CD4+ T cell population generated
during L. major infection is capable of developing
into either Th1 or Th2 effectors. Under the influence
of IL-12, Leishmania specific central memory CD4+
T cells get differentiated into IFN-  producing Th1
cells (Pakpour et al., 2008). Low dose L. major
promotes a transient Th2 response that is
downregulated by IFN-  producing CD8+ T cells
which may contribute to rapid resolution of secondary
lesions (Uzonna et al., 2004; Wang et al., 1993). It
has been reported that L. donovani infection augments
vaccine induced immunity to Listeria, enhancing the
host protective antigen specific memory CD8+ T cell
responses (Polley et al., 2005). In VL, generation of
antigen specific effector memory responses help in
protection against the disease by proliferation and
augmentation of CD62L–CD127+ CD4+/CD8+ T cells
(Mazumder et al., 2011a; Ravindran et al., 2012;
Roychoudhury et al., 2011; Mazumder et al., 2011b;
Mazumder et al., 2010; Bhowmick et al., 2008;
Mazumdar et al., 2004). It appears that effector
memory responses are more crucial than central
memory response for protection against VL but
further studies are required to clarify their roles.
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Th17 Cells
It was Harrington et al., (2005) who first reported
the presence of IL-17 (Harrington et al., 2005) and
classified Th17 subset as another member of CD4+T
cell lineage. The development of Th17 cells as a
distinct population from CD4+T cells is controlled
by a combination of cytokines like IL-6, IL-21, IL-
23, IL-1  and TGF- (Acosta-Rodriguez et al., 2007;
Chen et al., 2007; Liu and Rohowsky-Kochan 2008).
IL-23 is essential for generation and establishment
of IL-17 producing CD4+ T whereas TGF-  and IL-
6 are required for their priming (Cruz et al. 2006,
Bettelli et al., 2006; Mangan et al., 2006). Cytokine-
driven activation of the signal transducer and activator
of transcription (STAT) 3 pathway is an essential step
in Th17 cell differentiation (Holland et al., 2007).
This leads to the activation of a cascade of
transcription factors such as retinoid-acid receptor-
related orphan receptor- t  (ROR- t), chemokine (C-
C motif) receptor 6 (CCR6), Interferon regulatory
factor (IRF) 4, basic leucine zipper transcription
factor (BATF), FOXP3, T-bet, peroxisome
proliferator activated receptor (PPAR) , Fatty acid
binding protein and suppressor of cytokine signalling
(SOCS) protein (Hwang et al., 2010). Among them
CCR6 and ROR- t are well studied markers for the
identification of Th17 cells (Hirota et al., 2007).
Initially reports from murine CL suggested the
role of Th17 similar to Th2 responses as IL-17 was
observed to synergise with TGF-  in increasing
parasite load and disease pathology (Santarlasci 2009;
Bacellar 2009; Cezario 2011; Manel 2008). But as
studies progressed, Th17 response has emerged as
an additive to Th1 response which promotes initiation
of inflammatory response through neutrophil
chemotaxis and NO production (Reinhard et al., 2011;
Dudeck et al., 2011).  This ultimately helps in
reducing parasite burden in CL, PKDL, VL of mice
and human.  Other members of Th17 subset like IL-
22 and IL-23, along with IL-17, also play a significant
role in protection against different forms of
leishmaniasis like VL, CL, MCL, American
tegumentary leishmaniasis, PKDL and various other
diseases like tuberculosis, lung infection and
rheumatoid arthritis (Pitta et al., 2009; Khader et al.,
2007; Katara et al., 2012; de Assis et al., 2013; Ghosh
et al., 2013). Suppression of IL-17 by IL-10 and IL-
27 during Leishmania infection (Anderson et al.
2009; Gonzalez-Lombana et al., 2013; Owens et al.,
2012) furthermore supports the association of IL-17
with disease alleviation.  Additionally, exacerbation
of Leishmania suppresses LPS induced IL-17
production due to rise in Th2 responses (Lapara NJ
3rd and Kelly 2010). IL-17 being a promoter of Th1
response has been used in a combination with vaccine
and drugs for improving their effectiveness. Injection
of recombinant IL-17 with curdlan enhances its
therapeutic effect, thereby causing a marked increase
in generation of IFN-   along with NO and a
significant suppression of the organ parasite burden
during murine VL (Ghosh et al., 2013). CpG DNA
vaccine in the presence of live L. major causes
activation of neutrophil which leads to specific
induction of Th17 cells for IL-17 secretion leading
to enhancement in the development of a protective
cellular immunity against the parasite (Wu et al.,
2010). Even in the absence of Th1 response, Th17
shows some protection against leishmaniasis through
an unconventional pathway for activating effector T
cell responses (Pitta et al., 2009; Soong et al., 2012).
In addition to Th17 cells, IL-17 is shown to be
secreted from other cells like B cells, CD8+ T cells,
 T cells and neutrophils as well (Bermejo et al.,
2013; Li et al., 2010). IL-17, secreted from CD8+
cells is demonstrated to participate in the
inflammatory response to mucosal leishmaniasis
(Boaventura et al., 2010).
It is intriguing to note that Th17 cells have close
developmental link with CD4+ FOXP3+ regulatory
T cells (Tregs). FOXP3 and ROR- t can directly
interact via a DNA-independent mechanism, and
during Th17 cell development FOXP3 is transiently
expressed (Zhou et al., 2008). There are increasing
evidences for the existence of FOXP3+ cells that
could secrete IL-17 (Ayyoub et al., 2009; Kryczek et
al., 2011). Recent studies in murine CL advocate a
role of CCR6 in Treg cell rather than Th17 cell
recruitment during parasitic infections which depends
on cell-mediated immune response as the
predominant protective immune mechanism (Barth
et al., 2012). Further, it is shown that a balance
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between Treg and IL-17 control hepatic immune
responses. Increase in either of these two will lead to
parasite susceptibility (Zhao et al., 2010). But how
these two populations are interacting with each other
and whether their collective effect or individual
contribution is crucial for disease regression could
be a topic for future investigation.
Regulatory T Cells
Regulatory T cells are divided into “natural (or
constitutive)” and “induced (or adaptive)” Treg cells,
which may have complementary and overlapping
functions in immune regulation. Natural Treg (nTreg)
cells are developed in the thymus whereas inducible
Tregs (iTregs) are derived from the periphery under
the influence of DCs (Sakaguchi et al., 2010) and
can be either CD4+CD25+/– or CD8+CD25+/–. IL-10
secreted from APCs such as DCs or macrophages in
the periphery induce naïve T cells to become FOXP3-
Treg cells. This subset of regulatory cells secretes
IL-10 for active participation in immuno-modulation
and termed as Tr1 cell (Groux et al., 1997).
Additionally, TGF-  secreted from APCs can
induce the transformation of naïve T cells to a TGF-
 secreting Treg cells known as Th3 cells (Bilate and
Lafaille 2012). These two sub sets (viz. Tr1 and Th3)
of T cells are indispensable for maintaining immune
homeostasis.  Studies on the mechanism of action
and phenomenology of different types of Tregs
(Roncarolo et al., 2006; Workman et al., 2009) as
well as immune regulation by other T cell populations
like CD8+ T cells (Chang et al. 2002), CD4–CD8–T
cells (Zhang et al. 2000),  T cells (Hayday and
Tigelaar 2003) could help us in understanding the
mechanism involved in immunosuppression.
Treg cells are professed to use many cellular
processes to control immunosuppression.  Critical of
them are two core phenomena known as bystander
suppression and infectious tolerance. Suppressive
activity of Treg cells requires their prior activation
through their T cell receptors. Once potentiated, Treg
cells can induce immuno-suppression in an antigen-
nonspecific way called ‘bystander suppression’ (Qin
et al., 1993). Thus, Treg cells with one antigen
specificity can suppress T effector cells with many
other distinct antigen specificities (Wing and
Sakaguchi 2010). By infectious tolerance, one
population of suppressor T cells create a regulatory
milieu that promotes the outgrowth of a new
population of Treg cells with antigen specificities
distinct from those of the original Treg population.
This tolerant state induced by Treg cells is maintained
even after loss or removal of the original Treg cell
population (Qin et al., 1993; Sakaguchi et al., 2010;
Tarbell et al., 2007). Thus, through the processes of
bystander suppression and infectious tolerance, Treg
cells effectively maintain a state of stable tolerance
and immune regulation.
Several examples are there demonstrating the
immunosuppressive role of Treg cells in autoimmune
and infectious diseases, such as arthritis (Chen et al.,
2013), type-1 diabetes (Ryba-Stanislawowska et al.,
2013), asthma (Nawijn et al., 2013), HIV (Li et al.,
2013) and tuberculosis (Sharma et al. 2009; Ebinuma
et al., 2008). Studies of suppressive cells in
leishmaniasis go back to early 1970s when Bryceson
reported the emergence of antigen-specific immune
suppression during Leishmania infection (Bryceson
1970). It was further extended by Arredondo et al.
that the spleen cells from infected animal suppressed
normal lymphocytes (Arredondo and Perez, 1979)
and Howard et al.  who tried to characterize
suppressive T cell in murine models of L. tropica
infection (Howard et al., 1980; Howard et al., 1981).
Association of B cells with the development of
suppressive T cell (Sacks et al., 1987) and their active
involvement against both the inductive and expressive
phases of DTH response in CL were reported
(Dhaliwal et al., 1985). A potentially novel
immunoregulatory role for CD8+ T cells following
DNA vaccination has been reported in the last decade
(Gurunathan et al., 2000).  Our unpublished work on
murine VL also indicates the existence of
CD8+CD25+FOXP3 cells as potential regulatory cells
through secretion of IL-10 during the development
of the disease. CD8+ cells eliciting IL-10 have been
found to possess remarkable immunosuppressive
activity in autoimmune and infectious diseases (Noble
et al., 2006). Since 1995 when Sakaguchi and
colleagues defined CD4+ CD25+ cells as the most
important population of regulatory cells (Sakaguchi
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et al., 1995), the attention of studying Treg cells has
been restricted mainly to this population.
CD4+CD25+ regulatory T cells suppress both Th1 and
Th2 cells and these regulatory T cells have a profound
therapeutic potential against CL (Rodrigues et al.,
2013). Reports have recognized the involvement of
CD4+CD25+ Tregs in progression of CL caused by
both L. major (Belkaid et al., 2002) and L.
amazonensis in mice (Ji et al., 2005) and L.
braziliensis in humans (Campanelli et al., 2006). Treg
cells show suppressive role against human acute and
chronic CL by way of secreting IL-10 and suppressing
IFN- (Bourreau et al., 2009). With healing of CL,
the frequencies of CD4+CD25hiCD127 Treg cells
increased, showing their contribution in the resolution
of chronic dermal lesions (Tang et al., 2008). During
L. infantum infection in BALB/c mice, enrichment
of  CD4+CD25+FOXP3+ Treg cells have been shown
in the draining lymph nodes and spleen cells
(Rodrigues et al., 2009) suggesting  their association
with the disease. Involvement of CD4+CD25+ Treg
cells in progression of human VL and PKDL has also
been reported (Saha et al., 2007; Katara et al., 2011).
In PKDL a correlation of nTreg cells both with IL-10
levels and parasite burden emphasize their role in
disease severity (Katara et al., 2011). Interestingly,
reports from both human and murine CL suggest an
association between increased frequencies of
CD4+CD25hiCD127 Treg cells and resolution of
dermal lesions (Saha et al., 2007; Ji et al., 2005)
thereby indicating the contribution of Treg cells
towards cure of CL.
Till date the role of Tregs as the primary source
of IL-10 is controversial.  It has been shown in human
VL that rather than FOXP3+ T cells, Tr1 cells are the
major IL-10 producing cells and they are important
in suppressing  antileishmanial immunity and
conditioning host macrophage for enhanced parasite
survival and growth (Nylen et al., 2007; Stager et
al., 2006; Anderson et al., 2009; Maurya et al., 2010).
But recent reports advocate CD4+CD25+FOXP3+
cells as the major source of IL-10 in human VL having
high potential to suppress antileishmanial immune
responses (Rai et al., 2012). Similar observations
have also been made recently by Tiwanathagorn et
al., 2012 that CD4+FOXP3+ Treg cells induce IL-10
mediated L. donovani persistence in murine VL
(Tiwananthagorn et al., 2012).
Thus detailed investigations are required
regarding the immunosuppressive role played by
different regulatory T cell populations (viz., Tr1, Th3,
nTregs, iTregs and other cells) and the source(s) of
IL-10 for disease pathogenesis. Understanding the
nature of the major immunoregulatory cells and their
mechanism during leishmaniasis may not only unlock
new avenues towards novel target but also lead to
better intervention for disease cure.
Friends and Foes Among the Members of IL-12
Family
IL-12 family consists of heterodimeric cytokines, with
several distinctive features. It has many molecular
and functional characteristics that provide unique
opportunities for positive and negative feedback
control. Chain pairing promiscuity is a common
feature of this group’s member which includes IL-
12, IL-23, IL-27 and IL-35 (Collison and Vignali
2008; Jones and Vignali 2011). Despite many
structural similarities of these cytokines, their
receptors and downstream signalling components,
they have very different biological activities that
challenge their symphony. IL-12 and IL-23 are mainly
proinflammatory cytokines with key roles in the
development of the Th1 and Th17 subsets of T cells,
respectively (Kastelein et al., 2007; Pflanz et al.,
2002, Langrish et al., 2004). On the other hand  IL-
27 and recently identified IL-35 are known to play
regulatory roles both in human and mice (Collision
et al., 2010; Wojno and Hunter, 2012; Murugaiyan
et al., 2009; Perona-Wright et al., 2012; Collison,
2007; Vignali et al., 2008). These observations
establish a functionally balanced dichotomy in this
family, with IL-12 and IL-23 being positive and IL-
27 and IL-35 as negative regulators.
IL-12, the most extensively studied member of
this family is a key pro-inflammatory cytokine and
effective stimulant for the induction of an IFN-
mediated Th1 response during VL.  Phagocytic cells
like monocytes, macrophages, neutrophils and DCs
are the major source of IL-12 production (Scott P
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2003; Chan et al., 2006; dos Santos et al., 2008; Zaph
and Scott P 2003). IL-12 has a central role in
generating strong Th1 response with elevation in IFN-
 level in both murine and human VL (Saha et al.
2007; Banerjee et al. 2008; Zhang et al., 2013).
Susceptibility to experimental L. mexicana infection
was also attributed to IL-12 insensitiveness
(Rodriguez-Sosa et al., 2001). Similar observations
were made in human CL as well where IL-12
unresponsiveness was reported to be responsible for
the persistence of infection (Bourreau et al. 2001).
With the progression of disease, Th1 response
decreases and suppressive cytokines like IL-4, IL-10
and TGF-  increase promoting Th2 response. In the
absence of IL-12, increase in parasite load is
accompanied by decrease in IFN- , TNF-  and iNOS
production (Adhikari et al., 2012). During successful
therapy and vaccination, IL-12 promoting Th1
response corresponds with increase in IFN-  and NO
production leading to downregulation of Th2
responses accompanied by reduction in parasite
burden (Bhowmick et al., 2009; Mazumdar et al.,
2004). It has also been reported that even in the
absence of IFN- , IL-12 strongly promotes healing
(Murray et al., 2000; Adhikari et al., 2012; Satoskar
et al., 2000) emphasising indispensability of IL-12
in the induction of protective immunity against VL.
Another important and widely studied member
of this family is IL-27. It is an ongoing debate that
whether IL-27 drives a Th1 response or has a
pleiotropic effect on Th1, Th2 and Th17 as a key
regulatory cytokine that controls the balance between
immunity and pathology and their regulation
(Anderson et al., 2009; Hunter et al., 2004). Both
the hypotheses are supported by adequate evidences.
IL-27 has been shown to be critical for differentiation
and timely initiation of efficient anti-parasite Th1
immunity with enhanced IFN-  during infection
(Kamiya et al., 2004; Takeda et al., 2003; Zahn et
al., 2005).  Potential contribution of IL-27 along with
IL-17 in the control of L. braziliensis infection
(Novoa et al., 2011) by suppressing Th2 response
(Yoshimoto et al., 2007) has been shown. But recent
studies suggest IL-27 as a protective cytokine which
promotes antitumor immunity (Natividad et al., 2013)
as well as acts as a potent Th2 cytokine which
promotes tumor growth by inducing Treg cell
differentiation (Hunter and Kastelein 2012; Hall et
al., 2012; Murugaiyan and Saha 2013). Enhanced
plasma level of IL-27 both in human and mice during
healing and non-healing CL further support this
hypothesis (Tolouei et al., 2012).
In VL, significantly elevated levels of IL-27 at
both mRNA and plasma of VL patients suggested it
as a strong Th2 cytokine (Ansari et al., 2011).
Augmentation of IL-27 along with IL-21 leads to
expansion of IL-10 thereby causing disease
progression and parasite persistence. IL-27 has also
been reported to be involved in mediating
susceptibility to L. donovani, through interaction with
its T cell cytokine receptor (Rosas et al., 2006).
 Several recent studies have shown IL-27 to mediate
anti-inflammatory activity through its ability to
suppress Th17 cells (Batten et al., 2006; Stumhofer
et al., 2006) and induction of IL-10 from activated
CD4+ T cells. It is now being accepted that IL-27 is
critical for the generation of IL-10 producing CD4+T
cells in vitro (Awasthi et al., 2007; Fitzgerald et al.,
2007; Stumhofer et al., 2007), via signalling pathways
dependent on STAT3. Optimal production of IL-27
requires co-ordination of c-Maf (Musculoaponeurotic
Fibrosarcoma a proto-oncogene), inducible co-
stimulator (ICOS) and IL-21 expression (Apetoh et
al., 2010).  Emerging evidences also suggest that IL-
27 may directly alter methylation patterns around the
il10 promoter in CD4+T cells, thus allowing greater
IL-10 expression (Hedrich et al., 2010). IL-27 also
favours the production of IL-10 by IFN-  producing
Th1 cells through an alternate signalling pathway that
involves STAT1, STAT4 and Notch (Batten et al.,
2008; Rutz et al., 2008).
IL-35, a recently identified member, produced
by thymus-derived Treg cells has been reported to be
one of the potent regulatory cytokine in autoimmune
disease both in human and mice (Collison et al., 2010;
Collison et al., 2007; Vignali Collison et al., 2008).
IL-35 association has been shown with
atherosclerosis (Lin et al., 2012), hepatitis B (Liu et
al., 2011); leukemia (Wu et al., 2012), and tumor
(Olson et al., 2012; Wang et al., 2013), but its
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regulatory role in infectious diseases is yet to be
established. Association of IL-35 with the progression
of VL may lead to new targets for better intervention
and control of the disease.
Modulation of Signalling Pathways by L. donovani
Leishmania dampens host cell immune response by
modulating several key signalling pathways such as
nuclear factor- B (NF- B) and janus kinase (JAK)-
signal transducer and activator of transcription
(STAT) dependent pathways. NF- B has a critical
role in initiating innate immune response and in
protective Th1 mediated immunity. The Leishmania
parasite has been observed to evade NF-Kb activation
in infected macrophage and/or DC by promoting
cleavage of its RelA sub unit. As a result production
of pro-inflammatory cytokines and antimicobial
mediators such as iNOS is inhibited that allows
parasite survival and persistence within the host cell
(Reinhard et al. 2012). L. donovani infection modifies
NF-kB signalling by causing a specific cleavage of
p65RelA subunit. p35RelA, a cleavage fragment of
p65RelA then migrates to the nucleus and binds to
DNA as a heterodimer with NF-kB p50.  p35RelA/p50
dimer alters the  transcription of  several pro-
inflammatory cytokine and chemokine genes, thereby
subverting macrophage’s effector functions (Gregory
et al. 2008). Modulation of JAK/STAT pathway by
L. donovani attenuates IFN-  dependent macrophage
response. In addition, it downregulates IFN-  protein
receptor expression and upregulate a transient
expression of SOCS3 protein, a negative regulator
of IFN- signaling. Amastigote form of the parasite
has been reported to hinder nulear translocation of
STAT1  in response to IFN-  and compromises
STAT1 -nuclear transport adaptor importin- 5
interaction (Matte and Descoteaux 2010). Together,
modulation of these two pathways results in
downregulation of Th1 response with enhanced
survivability of the parasite.
Future Prospects
VL is a neglected tropical disease with a complex
immune mechanism. It remains a challenge to
understand its biology. Host immune defence
mechanism, triggered by the bite of sand fly, recruits
neutrophils and macrophages followed by NK cells
and DCs for the phagocytosis of the parasite. But the
mechanism involved in the establishment of L.
donovani infection and how these responses fail to
control the parasite propagation is not well
Fig. 1: Host immune response against L. donovani.With the parasite
entry polymorphonuclear neutrophils (PMNs) and
macrophages (M s) are recruited at the site of infection
and promastigotes are engulfed into phagosomes.
Neutrophils, secrete chemoattractants, CXCL-1, MIP-1
and CXCL-8 to engage more PMNs, M  and other immune
cells. M actively take up parasites either from fresh
inoculum or released from PMN. They may also take up
PMNs containing phagosytosed promastigotes surving as
Trogan horses. Chemoattractants, CCL-2 and CXCL-10
secreted by M  activate DCs and NK cells respectively, for
generation of various anti-leishmanial responses, such as
NK cell-mediated IL-12 secretion, and mast cell (MC)
primed DC-induction of CD8+ cells for cytolysis. CD4+ cells
under the influence of IL-12, IFN- , IL-10 and TGF-
cytokines from M  and DCs differentiate to give rise to (i)
IFN-  and TNF-  secreting Th1 cells (ii) IL-17 secreting
Th17 cells (iii) IL-4 and IL-13 producing Th2 cell and (iv)
IL-10 and TGF-  producing Treg cells for parasite
clearance/survival
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understood. Currently, the Trojan horse concept
explaining parasite survival within the neutrophils
during L. major infection could provide an answer,
but contradictory reports exist regarding its role in
protective response against infection. Moreover, there
is no such report available for its involvement in VL.
The understanding of the involvement of chemokines
as chemoattractants and cytokines to abridge innate
and adaptive immunity is important in Leishmania
infection. Studying the role of these chemokines in
clearing L. donovani parasites and modulating the
immune response against the parasite may unravel
future targets for immunotherapy. Among the
cytokines, IFN-  is crucial for priming protective Th1
responses, and along with IL-12, suppresses Th2
cytokines like IL-10 and IL-4. Nevertheless, there is
a lacuna in the use of such knowledge for the
development of contemporary approaches towards
combating the disease. Although IL-10 is proven to
be the principal cytokine involved in VL pathology,
and the use of anti IL-10 antibodies remains one of
the potent forms of immunotherapy against this
disease, contradiction still exists regarding its
source(s). Moreover, our understanding of the role
of different immune cells and their mechanism of
action against VL is still unclear. Although Tregs have
emerged as the most important cellular subset
responsible for disease pathogenesis, their nature and
mode of action for regulating the immune response
remains elusive. Recent research suggests Th17 as
an additive to Th1 response, but to what extent this
is true in controlling VL is unanswered. Involvement
of TGF-  in both Th17 cell priming and development
of Treg could also be looked upon as an important
issue. Members of IL-12 family are exceptionally
versatile, consisting of three  and two  chains, of
which one  and one  chain combine to give highly
diverse cytokines which could act in antagonism or
synergism in the generation of Th1 response. Studying
their unexploited combinations could lead to the
discovery of new cytokine networks and prospective
immunotherapeutic targets to combat the disease.
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